An AICD-based functional screen to identify APP metabolism regulators

Department of Bioscience & Biotechnology, Drexel University, Philadelphia, PA, USA. .
Molecular Neurodegeneration (Impact Factor: 6.56). 02/2007; 2(1):15. DOI: 10.1186/1750-1326-2-15
Source: PubMed


A central event in Alzheimer's disease (AD) is the regulated intramembraneous proteolysis of the beta-amyloid precursor protein (APP), to generate the beta-amyloid (Abeta) peptide and the APP intracellular domain (AICD). Abeta is the major component of amyloid plaques and AICD displays transcriptional activation properties. We have taken advantage of AICD transactivation properties to develop a genetic screen to identify regulators of APP metabolism. This screen relies on an APP-Gal4 fusion protein, which upon normal proteolysis, produces AICD-Gal4. Production of AICD-Gal4 induces Gal4-UAS driven luciferase expression. Therefore, when regulators of APP metabolism are modulated, luciferase expression is altered.
To validate this experimental approach we modulated alpha-, beta-, and gamma-secretase levels and activities. Changes in AICD-Gal4 levels as measured by Western blot analysis were strongly and significantly correlated to the observed changes in AICD-Gal4 mediated luciferase activity. To determine if a known regulator of APP trafficking/maturation and Presenilin1 endoproteolysis could be detected using the AICD-Gal4 mediated luciferase assay, we knocked-down Ubiquilin 1 and observed decreased luciferase activity. We confirmed that Ubiquilin 1 modulated AICD-Gal4 levels by Western blot analysis and also observed that Ubiquilin 1 modulated total APP levels, the ratio of mature to immature APP, as well as PS1 endoproteolysis.
Taken together, we have shown that this screen can identify known APP metabolism regulators that control proteolysis, intracellular trafficking, maturation and levels of APP and its proteolytic products. We demonstrate for the first time that Ubiquilin 1 regulates APP metabolism in the human neuroblastoma cell line, SH-SY5Y.

Download full-text


Available from: Srikant Sarangi,
  • Source
    • "The presence of Aβ oligomers and plaques is a neuropathological hallmark of Alzheimer's disease (Tiraboschi et al., 2004; Wang et al., 2012). Aβ is a proteolytic product formed by sequential proteolysis of APP (Wolfe, 2012; Zhang et al., 2007). It is known that Aβ deposition precedes neuronal degeneration as detected by Aβ CSF levels (Jack et al., 2012; Jack et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The biggest risk factor for developing Alzheimer's disease (AD) is age. Depending on the age of onset, AD is clinically categorized into either the early-onset form (before age 60years old), or the late-onset form (after age 65years old), with the vast majority of AD diagnosed as late onset (LOAD). LOAD is a progressive neurodegenerative disorder that involves the accumulation of β-amyloid (Aβ) plaques and neurofibrillary tangles in the brains of elderly patients. Affected individuals often experience symptoms including memory loss, confusion, and behavioral changes. Though many animal models of AD exist, very few are capable of analyzing the effect of older age on AD pathology. In an attempt to better model LOAD, we developed a novel "aged AD" model using Drosophila melanogaster. In our model, we express low levels of the human AD proteins APP (Amyloid Precursor Protein) and BACE1 (β-site APP cleaving enzyme BACE) specifically in the fly's central nervous system. Advantages of our model include the onset of behavioral and neuropathological symptoms later in the fly's lifespan due to gradual accrual of Aβ within the central nervous system (CNS), making age the key factor in the behavioral and neuroanatomical phenotypes that we observe in this model.
    Experimental Neurology 08/2014; 261. DOI:10.1016/j.expneurol.2014.08.021 · 4.70 Impact Factor
  • Source
    • "The extracellular amlyoid plaques are mainly composed of the amyloid beta (Aβ) peptide. Aβ is a peptide formed by proteolytic processing of the amyloid precursor protein (APP) (Zhang et al., 2007). APP processing occurs by one of two main pathways: the nonamyloidogenic pathway, or the amyloidogenic pathway (Chow et al., 2010; Zhang et al., 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's Disease (AD) is an age related neurodegenerative disease characterized by memory loss and decreased synaptic function. Advances in transgenic animal models of AD have facilitated our understanding of this disorder, and have aided in the development, speed, and efficiency of testing potential therapeutics. Recently, we have described the characterization of a novel model of AD in the fruit fly, Drosophila melanogaster, where we expressed the human AD associated proteins APP and BACE in the central nervous system of the fly. Here we describe synaptic defects in the larval neuromuscular junction (NMJ) in this model. Our results indicate that expression of human APP and BACE at the larval NMJ lead to defective larval locomotion behavior, decreased pre-synaptic connections, altered mitochondrial localization in presynaptic motor neurons, and decreased postsynaptic protein levels. Treating larvae expressing APP and BACE with the γ-secretase inhibitor L-685, 458 suppresses the behavioral defects as well as the pre- and postsynaptic defects. We suggest that this model will be useful to assess and model the synaptic dysfunction normally associated with AD, and will also serve as a powerful in vivo tool for rapid testing of potential therapeutics for AD.
    Disease Models and Mechanisms 01/2014; 7(3). DOI:10.1242/dmm.012104 · 4.97 Impact Factor
  • Source
    • "Carboxyl-terminal fragment (CTFβ or C99) of BACE1 processing can be further cleaved by γ-secretase, giving rise to Aβ [55]. Next, we examined the expressions of γ-secretase components: APH-1, nicastrin and PS-1, which cleave the C-terminals of Aβ. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Thalidomide is a tumor necrosis factor alpha (TNFα) inhibitor which has been found to have abilities against tumor growth, angiogenesis and inflammation. Recently, it has been applied in clinic for the treatment of multiple myeloma as well as some inflammatory diseases. However, whether thalidomide has any therapeutic effects on neurodegenerative disorders, i.e. Alzheimer's disease (AD) is not clear. AD is characterized by excessive amount of amyloid β peptides (Aβ), which results in a significant release of inflammatory factors, including TNFα in the brain. Studies have shown that inhibition of TNFα reduces amyloid-associated pathology, prevents neuron loss and improves cognition. Our recent report showed that genetic inhibition of TNFα/TNF receptor signal transduction down-regulates β amyloid cleavage enzyme 1 (BACE1) activity, reduces Aβ generation and improves learning and memory deficits. However, the mechanism of thalidomide involving in the mitigation of AD neuropathological features remains unclear. Here, we chronically administrated thalidomide on human APPswedish mutation transgenic (APP23) mice from 9 months old (an onset of Aβ deposits and early stage of AD-like changes) to 12 months old. We found that, in addition of dramatic decrease in the activation of both astrocytes and microglia, thalidomide significantly reduces Aβ load and plaque formation. Furthermore, we found a significant decrease in BACE1 level and activity with long-term thalidomide application. Interestingly, these findings cannot be observed in the brains of 12-month-old APP23 mice with short-term treatment of thalidomide (3 days). These results suggest that chronic thalidomide administration is an alternative approach for AD prevention and therapeutics.
    PLoS ONE 02/2013; 8(2):e55091. DOI:10.1371/journal.pone.0055091 · 3.23 Impact Factor
Show more